RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Chinese Suppliers Tied to Tainted Heparin

Chinese Suppliers Tied to Tainted Heparin

Posted 23 February 2012

Fourteen Chinese companies have been linked to contaminated heparin, an anticoagulant commonly used during surgical procedures and dialysis, according to a Wall Street Journal report.

The US Food and Drug Administration (FDA) added these companies to an import list allowing FDA to stop shipments at the border. That list already included eight other Chinese suppliers who were believe to have provided tainted raw materials for the making of heparin.

The Wall Street Journal reported the materials were delivered in 2008 and FDA doesn't have any evidence that the Chinese companies are currently supplying bad ingredients.

An estimated 12 million Americans use heparin each year, according to the report.

Read more:
The Wall Street Journal: Suppliers Linked to Impure Heparin
The New York Times: F.D.A. Lists Sources of Tainted Drug

 

© 2022 Regulatory Affairs Professionals Society.